Business Partners of Lotus Obtain First European Approvals For Generic Ulipristal 5mg

Oral oncology and specialty pharmaceutical Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, 1795:TT) today announced that its business partners, including Alvogen and many leading generic companies have successfully concluded 16 parallel decentralized procedures (DCP) for Ulipristal tablets. These companies have received regulatory clearance for its product in multiple European countries. This is the first approval of Ulipristal 5mg tablets in Europe.

Read More
1 2 3 4 5 ... 7

Highly experienced management team with a proven track record of achieving high growth and profitability.


News alert

Enter your email to sign up for news alerts